Business Context and Reporting Period
This Form 8-K was filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on January 12, 2007. The report details actions taken by the Compensation Committee regarding executive compensation adjustments and equity grants effective for the 2007 fiscal year.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and equity terms.
| Executive Officer | Title | Salary Increase | New Base Salary | Stock Options Granted |
|---|---|---|---|---|
| Joan M. Robbins | SVP and Chief Scientific Officer | $15,000 | $265,000 | 75,000 |
| Brian M. Culley | SVP and Chief Business Officer | $50,000 | $250,000 | 150,000 |
| Mark J. Cantwell | VP, Research and Development | $10,000 | $160,000 | 25,000 |
Material Changes
The primary material change is the approval of increased annual base salaries and new stock option grants for three named executive officers. No changes were made to the compensation of the Principal Executive Officer or Principal Financial Officer at this meeting.
Guidance, Outlook, and Terms
- Option Terms: All granted options have an exercise price of $2.75 per share, based on the closing price on the American Stock Exchange on January 12, 2007.
- Vesting Schedule: Options vest 25% on January 1, 2008, with the remainder vesting monthly (1/48th per month) thereafter, contingent on continuous service.
- Acceleration Clauses: Full acceleration occurs upon a change of control if the officer remains employed and options are not assumed. Partial acceleration (24-month vesting) applies in cases of involuntary termination within 24 months of a change of control.
- Plan Authority: Grants were made pursuant to the Company's 2005 Equity Incentive Plan.
Investor Verification Checklist
- Verify the correct registrant name is ADVENTRX Pharmaceuticals, Inc., as the input metadata referenced Savara Inc.
- Confirm the total dilution impact of 250,000 new options against the company's outstanding share count.
- Review the 2005 Equity Incentive Plan to understand the full scope of the "change of control" and "involuntary termination" definitions.
- Check subsequent filings to determine if the Principal Executive Officer received compensation adjustments in a different reporting period.